Boston Scientific entered into a definitive agreement to acquire Vertiflex, developer of the Superion® Indirect Decompression System, for US $465MM in cash plus contingency payments based on commercial milestones over three years. The transaction is slated to close in late 2Q19. Superion is expected to reach $60MM in 2019 revenue.
Superion creates space between the spinous processes of the vertebrae to improve function and reduce pain in lumbar spinal stenosis patients. The procedure is primarily performed by physicians who treat chronic pain patients with therapies such as spinal cord stimulation and radiofrequency ablation, which are offered by Boston Scientific within its pain management franchise.
“The acquisition of Vertiflex and the Superion System will further our category leadership strategy by expanding the breadth of our pain management product offerings,” said Maulik Nanavaty, President, Neuromodulation, Boston Scientific. “The addition of this differentiated technology, along with our leading spinal cord stimulation and radiofrequency ablation technologies, will provide physicians with the widest variety of solutions available to manage the growing number of patients suffering from chronic pain.”
Boston Scientific entered into a definitive agreement to acquire Vertiflex, developer of the Superion® Indirect Decompression System, for US $465MM in cash plus contingency payments based on commercial milestones over three years. The transaction is slated to close in late 2Q19. Superion is expected to reach $60MM in 2019 revenue. ...
Boston Scientific entered into a definitive agreement to acquire Vertiflex, developer of the Superion® Indirect Decompression System, for US $465MM in cash plus contingency payments based on commercial milestones over three years. The transaction is slated to close in late 2Q19. Superion is expected to reach $60MM in 2019 revenue.
Superion creates space between the spinous processes of the vertebrae to improve function and reduce pain in lumbar spinal stenosis patients. The procedure is primarily performed by physicians who treat chronic pain patients with therapies such as spinal cord stimulation and radiofrequency ablation, which are offered by Boston Scientific within its pain management franchise.
“The acquisition of Vertiflex and the Superion System will further our category leadership strategy by expanding the breadth of our pain management product offerings,” said Maulik Nanavaty, President, Neuromodulation, Boston Scientific. “The addition of this differentiated technology, along with our leading spinal cord stimulation and radiofrequency ablation technologies, will provide physicians with the widest variety of solutions available to manage the growing number of patients suffering from chronic pain.”
Copy to clipboard 
